Related Experiment Video
Updated: Aug 2, 2026

17:28
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
The state and future requirements of teratogenic testing
Summary
This study compares experimental teratology results across labs to support teratological testing programs. Basic requirements for embryotoxicity tests are also outlined to improve developmental toxicity assessments.
Area of Science:
- Developmental Biology
- Toxicology
- Reproductive Science
Background:
- Experimental teratology involves studying birth defects and developmental abnormalities.
- Standardized testing is crucial for reliable assessment of teratogenic potential.
- Variability in laboratory results can impact safety evaluations.
Purpose of the Study:
- To compare and synthesize findings in experimental teratology from various laboratories.
- To derive conclusions supporting the establishment and refinement of teratological test programs.
- To formulate essential requirements for conducting robust embryotoxicity tests.
Main Methods:
- Comparative analysis of published and unpublished experimental teratology data.
- Synthesis of author's practical experience in the field.
- Identification of commonalities and discrepancies in reported results.
Main Results:
- Consistent findings across laboratories support specific teratological endpoints.
- Author's experience highlights practical challenges and solutions in teratology testing.
- Identified key parameters for successful embryotoxicity assessments.
Conclusions:
- Established conclusions provide a foundation for standardized teratological test programs.
- Formulated requirements enhance the reliability and reproducibility of embryotoxicity testing.
- Recommendations support the advancement of developmental toxicology research and safety evaluation.
More Related Videos
Related Concept Videos
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

